Showing 796 results
- Media Release /- Overall survival results from MONALEESA-7 with Kisqali® (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO- Primary results…
- Media Release /-The Solutions to Empower Patients (STEP) Program™ continues to help nonprofit organizations deliver new solutions to address unmet patient needs-This year's focus is on addressing some of the most…
- Media Release /- Voluntary recall of three lots issued after discovering potential cross contamination at a third-party manufacturer- Patients taking Promacta 12.5 mg for oral suspension should contact 1-866-918-…
- Media Release /- One-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA- Annualized cost of Zolgensma is USD 425,000…
- Media Release /- SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2[1,2]-…
- Media Release /- Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (…
- Media Release /- FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from…
- Media Release /- BRAF mutation status is an important factor when choosing a first-line therapy for patients with stage III and stage IV melanoma- The Know Now Testing Program covers cost of this genetic mutation…
- Media Release /- Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine-…
- Media Release /BASEL, Switzerland, Sept. 19, 2019 /PRNewswire/ -- New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age‑appropriate…
Pagination
- ‹ Previous page
- 1
- …
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- …
- 80
- › Next page